Effect of G-CSF on induction of ENA-78 and IL-8 in the patients with malignant lymphoma.
Granulocyte colony stimulating factor (G-CSF) restores neutrophil count in patients with chemotherapy-induced neutropenia. G-CSF can also induce production of epithelial neutrophil activating protein-78 (ENA-78) and interleukin-8 (IL-8), chemotactic factors from neutrophils in vitro. This study was purposed to investigate whether this effect is also observed in vivo. 10 lymphoma patients were selected who received chemotherapy and G-CSF (nartograstim) administration. Blood was obtained before chemotherapy [Time Point 1 (TP1)], at neutropenic phase before G-CSF administration (TP2), and at neutrophil recovery phase after G-CSF (TP3). ENA-78 and IL-8 mRNA in neutrophils were quantified by real-time PCR. Phagocytosis and reactive oxygen species (ROS) generation were examined by flow cytometry. The results showed that ENA-78 and IL-8 mRNA expression at TP2 increased in 5 and 8 patients, respectively. The ENA-78 mRNA expression at TP3 was increased in 3 and decreased in 6 patients, and IL-8 mRNA expression at TP3 decreased in 7 patients. G-CSF did not affect phagocytosis and normalized ROS generation in all of the patient. It is concluded that increase of ENA-78 and IL-8 expression in neutrophils is common in chemotherapy-induced neutropenic patients. G-CSF administration does not significantly increase ENA-78 and IL-8 expression.
Department of Hematology, The Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an 71004, Shaanxi Province, China.
Wan-Hong
WH
Zhao
Department of Hematology, The Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an 71004, Shaanxi Province, China.
Shan
S
Meng
Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo113-8603, Japan. E-mail: tam@nms.ac.jp.
Hideto
H
Tamura
Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo113-8603, Japan.
Asaka
A
Kond
Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo113-8603, Japan.
Kiyoyuki
K
Ogata
Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo113-8603, Japan.
Kazuo
K
Dan
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D054365:Chemokine CXCL5 / Q000378:metabolism*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D008223:Lymphoma / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics
C486263:CXCL5 protein, human; C508606:CXCL8 protein, human; D054365:Chemokine CXCL5; D016209:Interleukin-8; D012333:RNA, Messenger; D016178:Granulocyte-Macrophage Colony-Stimulating Factor